
Sheila Gujrathi
QuietNamed in filings at SilverArc PrivateOn the current fund
- Board seats filed
- 7

Named in filings at SilverArc PrivateOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Prana Therapies | Biotech & pharma | May 2024 | Curie Bio |
| Lila Biologics | Biotech & pharma | September 2023 | None on file |
| Janux Therapeutics | Biotech & pharma | April 2021 | None on file |
| Ventyx Biosciences | Biotech & pharma | February 2021 | Venbio Global Strategic |
| ADARx Pharmaceuticals | Biotech & pharma | November 2020 | Bain Capital Life Sciences, SR One, TCG Crossover, Vivo Capital |
| TP Therapeutics | Biotech & pharma | October 2018 | SR One, Venbio Global Strategic, Vivo Capital |
| Receptos | Biotech & pharma | February 2012 | ARCH Venture Partners, Polaris Partners |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The category is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Categories of companies where filings name Sheila Gujrathi on the board, based on 7 filed seats with a verified or cited source.